GC
Glessner Coleen
VP Exécutif
OFFICERF
Insider track record
ExecutiveNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Glessner Coleen, VP Exécutif. Director active across 1 company, notably Emergent BioSolutions Inc.. In total, 19 reports have been logged. Breakdown: 0 buy · 1 sell. Total volume traded: €263k. Activity tracked since 8 April 2022. The latest transaction was disclosed on 29 April 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Glessner Coleen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
2,018 sharesCommon StockSEC:0001919170-26-000016:0
100,111 shares0Common StockSEC:0001919170-26-000012:0
8,199 shares@ US$8.447.7% of flowCommon StockSEC:0001919170-26-000009:0
313 shares@ US$8.150.3% of flowCommon StockSEC:0001919170-26-000006:0
28,847 shares@ US$10.9234.8% of flowCommon StockSEC:0001919170-26-000003:0
30,608 shares@ US$10.000.064% mcap50.0% of flowCommon StockSEC:0001919170-25-000004:0
1,249 shares@ US$6.631.6% of flowCommon StockSEC:0001367644-25-000143:0
480 shares@ US$4.440.3% of flowCommon StockSEC:0001367644-25-000092:0
62,500 shares0Common StockSEC:0001367644-25-000047:0
5,913 shares0Common StockSEC:0001367644-25-000034:0
18,674 shares@ US$9.0122.8% of flowCommon StockSEC:0001367644-24-000191:0
1,249 shares@ US$6.191.0% of flowCommon StockSEC:0001367644-24-000106:0
585 shares@ US$2.290.2% of flowCommon StockSEC:0001367644-24-000049:0
381 shares@ US$3.390.2% of flowCommon StockSEC:0001367644-24-000024:0
15,385 shares0Common StockSEC:0001367644-23-000124:0
480 shares0Common StockSEC:0001367644-23-000080:0
3,846 shares0Common StockSEC:0001367644-23-000070:0
24,078 shares0Common StockSEC:0001367644-22-000156:0
5,913 shares0Common StockSEC:0001367644-22-000063:0
About Glessner Coleen
Coleen Glessner is the Executive Vice President of Quality and Ethics at Emergent BioSolutions Inc. She oversees the company's quality and ethics initiatives, ensuring compliance and integrity in operations. Her role is crucial for Emergent's reputation.